Literature DB >> 11920310

Relationship of hepatitis C genotype 1 NS5A sequence mutations to early phase viral kinetics and interferon effectiveness.

Deborah A Schiappa1, Chetna Mittal, Jennifer A Brown, Brian P Mika.   

Abstract

The interferon (IFN) sensitivity-determining region (ISDR) of the hepatitis C virus (HCV) NS5A protein is controversially implicated in determining IFN-alpha-sustained viral response for HCV genotype 1-infected patients. Because the NS5A protein interferes with protein kinase antiviral activity, this study attempted to determine whether ISDR amino acid mutation number would correlate better with IFN effectiveness to inhibit virus production and elicit early virus clearance. Early viral kinetic data from 22 genotype 1-infected patients treated with high-dose IFN was compared with ISDR mutation number. IFN effectiveness and first-phase viral log decline correlated directly with ISDR mutation number (P=.02). Mean mutation number was higher among rapid responders (3.7+/-1.0; n=6) than among nonresponders (1.3+/-1.0; n=16) (P=.001). Also, second-phase viral log decline and calculated hepatocyte death rate correlated directly with ISDR mutation number (P=.01). This supports a dual effector role for NS5A, which regulates virus production and immune clearance early in therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920310     DOI: 10.1086/339485

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA.

Authors:  Jashmin Vyas; Androulla Elia; Michael J Clemens
Journal:  RNA       Date:  2003-07       Impact factor: 4.942

2.  Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load.

Authors:  Koji Ishii; Mie Shinohara; Michio Kogame; Misato Shiratori; Katsuya Higami; Kaori Kanayama; Kazue Shiozawa; Noritaka Wakui; Hidenari Nagai; Manabu Watanabe; Yasukiyo Sumino
Journal:  Hepatol Int       Date:  2011-08-06       Impact factor: 6.047

Review 3.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

4.  HCV replication in PBMC and its influence on interferon therapy.

Authors:  Guo-Zhong Gong; Li-Ying Lai; Yong-Fang Jiang; Yan He; Xian-Shi Su
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 5.  Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action.

Authors:  M A García; J Gil; I Ventoso; S Guerra; E Domingo; C Rivas; M Esteban
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

Review 6.  An overview of HCV molecular biology, replication and immune responses.

Authors:  Usman A Ashfaq; Tariq Javed; Sidra Rehman; Zafar Nawaz; Sheikh Riazuddin
Journal:  Virol J       Date:  2011-04-11       Impact factor: 4.099

7.  HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding.

Authors:  Guo-Zhong Gong; Yong-Fang Jiang; Yan He; Li-Ying Lai; Ying-Hua Zhu; Xian-Shi Su
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.